| Literature DB >> 26453961 |
Katrin Pfütze1, Axel Benner2, Michael Hoffmeister3, Lina Jansen3, Rongxi Yang4, Hendrik Bläker5, Esther Herpel6, Alexis Ulrich7, Cornelia M Ulrich8, Jenny Chang-Claude9, Hermann Brenner10, Barbara Burwinkel4.
Abstract
DNA methylation variations in gene promoter regions are well documented tumor-specific alterations in human malignancies including colon cancer, which may influence tumor behavior and clinical outcome. As a subset of colon cancer patients does not benefit from adjuvant chemotherapy, predictive biomarkers are desirable. Here, we describe that DNA methylation levels at CpG loci of hyaluronoglucosaminidase 2 (HYLA2) could be used to identify stage II and III colon cancer patients who are most likely to benefit from 5-flourouracil (5-FU) chemotherapy with respect to overall survival and progression-free survival.Entities:
Keywords: 5-FU; Chemotherapy; Colorectal cancer; DNA methylation; HYAL2; Predictive marker; Prognostic marker
Mesh：
Substances：
Year: 2015 PMID： 26453961 DOI： 10.1016/j.ygeno.2015.10.002
Source DB: PubMed Journal: Genomics ISSN： 0888-7543 Impact factor: 5.736